Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Tuberculosis

  Free Subscription


02.04.2018

10 Eur Respir J
1 Int J Tuberc Lung Dis
1 J Antimicrob Chemother
1 J Clin Microbiol
2 J Immunol
4 Lancet
3 Lancet Glob Health
7 Lancet Infect Dis
1 Lancet Public Health
10 Lancet Respir Med
1 PLoS Med
3 PLoS One
1 Proc Natl Acad Sci U S A
1 Trop Med Int Health


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Eur Respir J

  1. TIBERI S, Payen MC, Sotgiu G, D'Ambrosio L, et al
    Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis.
    Eur Respir J. 2018;51.
    PubMed     Text format    

  2. JAFARI C, Olaru ID, Daduna F, Ernst M, et al
    Rapid diagnosis of pulmonary tuberculosis by combined molecular and immunological methods.
    Eur Respir J. 2018 Mar 29. pii: 13993003.02189-2017.
    PubMed     Text format     Abstract available

  3. HALLEUX CM, Falzon D, Merle C, Jaramillo E, et al
    The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis.
    Eur Respir J. 2018;51.
    PubMed     Text format    

  4. MUNOZ-TORRICO M, Salazar MA, Millan MJM, Martinez Orozco JA, et al
    Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico.
    Eur Respir J. 2018;51.
    PubMed     Text format    

  5. RUDGARD WE, das Chagas NS, Gayoso R, Barreto ML, et al
    Uptake of governmental social protection and financial hardship during drug-resistant tuberculosis treatment in Rio de Janeiro, Brazil.
    Eur Respir J. 2018;51.
    PubMed     Text format    

  6. MUSVOSVI M, Duffy D, Filander E, Africa H, et al
    T-cell biomarkers for diagnosis of tuberculosis: candidate evaluation by a simple whole blood assay for clinical translation.
    Eur Respir J. 2018;51.
    PubMed     Text format    

  7. GILPIN C, Korobitsyn A, Migliori GB, Raviglione MC, et al
    The World Health Organization standards for tuberculosis care and management.
    Eur Respir J. 2018;51.
    PubMed     Text format    

  8. DE VRIES G, van den Hof S, Op de Coul E, van Crevel R, et al
    Closing the gap in surveillance of tuberculosis and HIV co-infection, and the need for clinician-public health alliances.
    Eur Respir J. 2018;51.
    PubMed     Text format    

  9. LYLES G, Ogarkov O, Zhdanova S, Peloquin CA, et al
    Pharmacokinetics of tuberculosis drugs in HIV infected patients from Irkutsk, Russian Federation: redefining drug activity.
    Eur Respir J. 2018 Mar 29. pii: 13993003.00109-2018.
    PubMed     Text format    

  10. SAUNDERS MJ, Tovar MA, Datta S, Evans BEW, et al
    Pragmatic tuberculosis prevention policies for primary care in low- and middle-income countries.
    Eur Respir J. 2018;51.
    PubMed     Text format    


    Int J Tuberc Lung Dis

  11. JACOBS C, Goussard P, Gie RP
    Mycobacterium tuberculosis, a cause of necrotising pneumonia in childhood: a case series.
    Int J Tuberc Lung Dis. 2018 Mar 22. doi: 10.5588/ijtld.17.0570.
    PubMed     Text format     Abstract available


    J Antimicrob Chemother

  12. CANEZIN PH, Caleffi-Ferracioli KR, Scodro RBL, Siqueira VLD, et al
    Intramacrophage Mycobacterium tuberculosis efflux pump gene regulation after rifampicin and verapamil exposure.
    J Antimicrob Chemother. 2018 Mar 22. pii: 4951545. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Clin Microbiol

  13. HILLEMANN D, Haasis C, Andres S, Behn T, et al
    Validation of the FluoroType(R) MTBDR assay for the detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis complex isolates.
    J Clin Microbiol. 2018 Mar 28. pii: JCM.00072-18. doi: 10.1128/JCM.00072.
    PubMed     Text format     Abstract available


    J Immunol

  14. BUREL JG, Lindestam Arlehamn CS, Khan N, Seumois G, et al
    Transcriptomic Analysis of CD4(+) T Cells Reveals Novel Immune Signatures of Latent Tuberculosis.
    J Immunol. 2018 Mar 30. pii: jimmunol.1800118. doi: 10.4049/jimmunol.1800118.
    PubMed     Text format     Abstract available

  15. MICHELET X, Tuli A, Gan H, Geadas C, et al
    Lysosome-Mediated Plasma Membrane Repair Is Dependent on the Small GTPase Arl8b and Determines Cell Death Type in Mycobacterium tuberculosis Infection.
    J Immunol. 2018 Mar 28. pii: jimmunol.1700829. doi: 10.4049/jimmunol.1700829.
    PubMed     Text format     Abstract available


    Lancet

  16. DAVIES R
    Leo Martinez: striving to end childhood tuberculosis.
    Lancet. 2018 Mar 21. pii: S0140-6736(18)30680.
    PubMed     Text format    

  17. WINGFIELD T, Tovar MA, Datta S, Saunders MJ, et al
    Addressing social determinants to end tuberculosis.
    Lancet. 2018;391:1129-1132.
    PubMed     Text format    

  18. GOOSBY E, Jamison D, Swaminathan S, Reid M, et al
    The Lancet Commission on tuberculosis: building a tuberculosis-free world.
    Lancet. 2018;391:1132-1133.
    PubMed     Text format    

  19. SHARMA D
    Commitments to an end to tuberculosis renewed in India.
    Lancet. 2018;391:1138.
    PubMed     Text format    


    Lancet Glob Health

  20. MIGLIORI GB, Garcia-Basteiro AL
    Predicting the effect of improved socioeconomic health determinants on the tuberculosis epidemic.
    Lancet Glob Health. 2018 Mar 23. pii: S2214-109X(18)30189.
    PubMed     Text format    

  21. DETJEN AK, McKenna L, Graham SM, Marais BJ, et al
    The upcoming UN general assembly resolution on tuberculosis must also benefit children.
    Lancet Glob Health. 2018 Mar 23. pii: S2214-109X(18)30108.
    PubMed     Text format    

  22. CARTER DJ, Glaziou P, Lonnroth K, Siroka A, et al
    The impact of social protection and poverty elimination on global tuberculosis incidence: a statistical modelling analysis of Sustainable Development Goal 1.
    Lancet Glob Health. 2018 Mar 23. pii: S2214-109X(18)30195.
    PubMed     Text format     Abstract available


    Lancet Infect Dis

  23. HILL-CAWTHORNE GA
    Population monitoring for drug-resistant tuberculosis: is genomics the answer?
    Lancet Infect Dis. 2018 Mar 21. pii: S1473-3099(18)30161.
    PubMed     Text format    

  24. ZIGNOL M, Cabibbe AM, Dean AS, Glaziou P, et al
    Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study.
    Lancet Infect Dis. 2018 Mar 21. pii: S1473-3099(18)30073.
    PubMed     Text format     Abstract available

  25. HERBERT N, Sharma V, Masham BS, Sheehan BS, et al
    Concrete action now: UN High-Level Meeting on Tuberculosis.
    Lancet Infect Dis. 2018 Mar 23. pii: S1473-3099(18)30171.
    PubMed     Text format    

  26. WALZL G, McNerney R, du Plessis N, Bates M, et al
    Tuberculosis: advances and challenges in development of new diagnostics and biomarkers.
    Lancet Infect Dis. 2018 Mar 23. pii: S1473-3099(18)30111.
    PubMed     Text format     Abstract available

  27. TIBERI S, du Plessis N, Walzl G, Vjecha MJ, et al
    Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.
    Lancet Infect Dis. 2018 Mar 23. pii: S1473-3099(18)30110.
    PubMed     Text format     Abstract available

  28. CLARY J, Dean R
    Tuberculosis on Lesvos: barriers to treatment.
    Lancet Infect Dis. 2018;18:377-378.
    PubMed     Text format    

  29. TAGLIANI E, Cirillo DM, Kodmon C, van der Werf MJ, et al
    EUSeqMyTB to set standards and build capacity for whole genome sequencing for tuberculosis in the EU.
    Lancet Infect Dis. 2018;18:377.
    PubMed     Text format    


    Lancet Public Health

  30. GODREUIL S, Marcy O, Wobudeya E, Bonnet M, et al
    Tackling mortality due to childhood tuberculosis.
    Lancet Public Health. 2018 Mar 23. pii: S2468-2667(18)30049.
    PubMed     Text format    


    Lancet Respir Med

  31. ESMAIL H, Dodd PJ, Houben RMGJ
    Tuberculosis transmission during the subclinical period: could unrelated cough play a part?
    Lancet Respir Med. 2018;6:244-246.
    PubMed     Text format    

  32. PENN-NICHOLSON A, Tameris M, Smit E, Day TA, et al
    Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
    Lancet Respir Med. 2018;6:287-298.
    PubMed     Text format     Abstract available

  33. FREGONESE F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, et al
    Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.
    Lancet Respir Med. 2018;6:265-275.
    PubMed     Text format     Abstract available

  34. MUHJAZI G, Baghdadi S, Dye C, Qusaibaty M, et al
    Sustaining a national tuberculosis control programme during civil crisis: 6 years of experience in Syria.
    Lancet Respir Med. 2018;6:255-256.
    PubMed     Text format    

  35. BALAKRISHNAN VS
    The changing face of tuberculosis care in Russia.
    Lancet Respir Med. 2018;6:249-250.
    PubMed     Text format    

  36. LIENHARDT C, Zumla A, Gebreselassie N, Frick M, et al
    Tuberculosis research and development: seeding the future.
    Lancet Respir Med. 2018;6:242-244.
    PubMed     Text format    

  37. DHEDA K, Gumbo T, Lange C, Horsburgh CR Jr, et al
    Pan-tuberculosis regimens: an argument against.
    Lancet Respir Med. 2018;6:240-242.
    PubMed     Text format    

  38. WALLIS RS, Cohen T, Menzies NA, Churchyard G, et al
    Pan-tuberculosis regimens: an argument for.
    Lancet Respir Med. 2018;6:239-240.
    PubMed     Text format    

  39. MIGLIORI GB, Tiberi S, Sotgiu G
    Defining the best regimen to treat isoniazid-resistant tuberculosis.
    Lancet Respir Med. 2018;6:233-235.
    PubMed     Text format    

  40. FLOYD K, Glaziou P, Zumla A, Raviglione M, et al
    The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era.
    Lancet Respir Med. 2018;6:299-314.
    PubMed     Text format     Abstract available


    PLoS Med

  41. PAI M
    Time for high-burden countries to lead the tuberculosis research agenda.
    PLoS Med. 2018;15:e1002544.
    PubMed     Text format     Abstract available


    PLoS One

  42. STOCKBRIDGE EL, Miller TL, Carlson EK, Ho C, et al
    Private sector tuberculosis prevention in the US: Characteristics associated with interferon-gamma release assay or tuberculin skin testing.
    PLoS One. 2018;13:e0193432.
    PubMed     Text format     Abstract available

  43. TAKAKI K, Ramakrishnan L, Basu S
    A zebrafish model for ocular tuberculosis.
    PLoS One. 2018;13:e0194982.
    PubMed     Text format     Abstract available

  44. DENNIS EM, Hao Y, Tamambang M, Roshan TN, et al
    Tuberculosis during pregnancy in the United States: Racial/ethnic disparities in pregnancy complications and in-hospital death.
    PLoS One. 2018;13:e0194836.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  45. CROWE AM, Workman SD, Watanabe N, Worrall LJ, et al
    IpdAB, a virulence factor in Mycobacterium tuberculosis, is a cholesterol ring-cleaving hydrolase.
    Proc Natl Acad Sci U S A. 2018 Mar 26. pii: 1717015115.
    PubMed     Text format     Abstract available


    Trop Med Int Health

  46. YELLAPPA V, Battaglioli T, Gurum SK, Narayanan D, et al
    Involving private practitioners in the Indian tuberculosis program: a randomized trial.
    Trop Med Int Health. 2018 Mar 25. doi: 10.1111/tmi.13053.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: